| Dr Kathy Denise Robinson, | |
|
1088a Park Circle Nw, Conyers, GA 30012-4446 | |
| (770) 601-7784 | |
| Not Available |
| Full Name | Dr Kathy Denise Robinson |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 1088a Park Circle Nw, Conyers, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093094229 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 006122 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kathy Denise Robinson, 1088a Park Circle Nw, Conyers, GA 30012-4446 Ph: (770) 601-7784 | Dr Kathy Denise Robinson, 1088a Park Circle Nw, Conyers, GA 30012-4446 Ph: (770) 601-7784 |
News Archive
Oxford Outcomes, an international health outcomes consultancy, has become a member of SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.
In the future, explained Peter Ghazal, Chair of Edinburgh University's Department of Molecular Genetics and Biomedicine, biological sensors, the product of the integration of biology and electronics will be used to detect infections and prescribe personalized treatments.
A new study presented this week at The Liver Meeting - held by the American Association for the Study of Liver Diseases - found that eradication of the hepatitis C virus induced by direct‐acting antiviral medications is associated with a 71 percent reduction in the risk of liver cancer.
Glycosylated proteins are often overexpressed in tumor cells and thus could serve as tumor markers, especially those with the interesting molecule sialic acid as their sugar moiety.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
› Verified 6 days ago
Mr. Solomon Berewa, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1000 Iris Dr Sw Ste D200, Conyers, GA 30094 Phone: 404-396-7890 | |
Crystal N. Broughton, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1775 Parker Rd Se Ste 210, Conyers, GA 30094 Phone: 470-967-8663 Fax: 678-218-4253 | |
Michelle M. Billups, Counselor Medicare: Not Enrolled in Medicare Practice Location: 977a Taylor St Sw, Conyers, GA 30012 Phone: 770-918-6677 | |
Dandrea R Sanders, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1780b Southgate Ln Se, Conyers, GA 30013 Phone: 470-207-2044 | |
Leroy Bryan, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1175 Green St Se, Conyers, GA 30012 Phone: 770-929-1470 | |
Debra Lavette Hanson, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3204 Quincey Xing, Conyers, GA 30013 Phone: 404-803-1127 | |
Maurvet Minto, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1175 Green St, Conyers, Conyers, GA 30012 Phone: 256-970-8503 |